Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Sophia Genetics S.A.
Headquarters: Saint Sulpice, Switzerland
Website: http://www.sophiagenetics.com...
Year Founded: 2011
Status: Public
Industry Sector: TechnologyServices
CEO: Jurgi Camblong, PhD, EMBA
Number Of Employees: 423
Enterprise Value: $152,615,006
PE Ratio: -3.17
Exchange/Ticker 1: NASDAQ:SOPH
Exchange/Ticker 2: N/A
Latest Market Cap: $219,874,304
BioCentury | Apr 30, 2024
Deals
Deals Report: BMS-Repertoire to develop vaccines for autoimmunity
Plus: Regeneron, Mammoth to make CRISPR-based gene editing therapies, and updates from Vertex-TreeFrog, Ono-Deciphera and more
BioCentury | Mar 15, 2023
Finance
March 14 Quick Takes: Switch launches with $52M and conditional gene knockdown tech
Plus: Servier’s vorasidenib meets glioma endpoint and updates from Teitur, AlgoTx, GSK, Acesion, Sophia Genetics and more
BioCentury | Aug 27, 2021
Finance
Rising aMoon and its growing portfolio at the healthcare-tech interface
Israeli VC has a stable of 36 therapeutics, health-tech plays, with plans to ramp up company creation
BioCentury | Jul 23, 2021
Finance
Caribou gives back early gains after pricing $304M IPO
Gene editing company draws on recent investor interest in sector
BioCentury | Oct 2, 2020
Finance
Sophia aims to parlay expertise of new backers aMoon, Hitachi to grow biopharma business
Swiss genomics company raises $110M in series F round
BioCentury | Feb 27, 2020
Product Development
Feb. 26 Quick Takes: Takeda acquires PvP for celiac therapy; plus Lilly, Esperion, Supernus, Moderna, Taiho-Arcus, Twist-Sophia
BioCentury | Feb 22, 2020
Management Tracks
Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more
BioCentury | Feb 15, 2020
Management Tracks
Immunomedics names Itri CMO; plus Hua, GenMark, AAM, Vividion, Sophia Genetics, Enterprise, Encoded, Palleon and more
Items per page:
1 - 10 of 17